Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update
M Salmon, HE White, NCP Cross… - Chronic Myeloid …, 2021 - Springer
Serial quantification of BCR-ABL1 mRNA levels is a sensitive and specific measure of
response to therapy in patients with chronic myeloid leukemia and is used to define time …
response to therapy in patients with chronic myeloid leukemia and is used to define time …
Chronic myelogenous leukemia: monitoring response to therapy
S Branford, J Prime - Current hematologic malignancy reports, 2011 - Springer
Molecular monitoring is a key component of the management of patients with chronic
myeloid leukemia. The current recommendation is that molecular monitoring be performed …
myeloid leukemia. The current recommendation is that molecular monitoring be performed …
[HTML][HTML] Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post–Allogeneic Stem Cell Transplantation …
M Koren-Michowitz, A Shimoni, F Daraio… - Biology of Blood and …, 2015 - Elsevier
Real-time quantitative PCR (RT-qPCR) is commonly used for follow-up of chronic myeloid
leukemia (CML) patients treated with tyrosine kinase inhibitors, but its current sensitivity …
leukemia (CML) patients treated with tyrosine kinase inhibitors, but its current sensitivity …
Transplant to treatment-free remission: The evolving view of 'cure'in chronic myeloid leukemia
ASM Yong, E Brissot, S Rubinstein… - Expert Review of …, 2015 - Taylor & Francis
Before the introduction of the BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib, chronic
myeloid leukemia (CML) was the leading indication for allogeneic hematopoietic stem cell …
myeloid leukemia (CML) was the leading indication for allogeneic hematopoietic stem cell …
Development of an inverse-PCR approach for characterization of the major BCR-ABL1 breakpoint sequences on genomic DNA: proof of concept
LG Gutiérrez, MM Abelleyro, MS Ruiz… - Clinical Chemistry and …, 2021 - degruyter.com
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the
presence of the Philadelphia chromosome, which contains the BCR-ABL1 fusion gene. The …
presence of the Philadelphia chromosome, which contains the BCR-ABL1 fusion gene. The …
[图书][B] The genetic basis of haematological cancers
S Tosi, AG Reid - 2016 - books.google.com
Written by a team of international experts, this book provides an authoritative overview and
practical guide to the molecular biology and genetic basis of haematologic cancers …
practical guide to the molecular biology and genetic basis of haematologic cancers …
Identification of the genomic BCR-ABL1 fusion sequence from blood specimen stored on filter paper
M Karl, M Krumbholz, JT Tauer, U Jacobs, M Metzler… - Leukemia Research, 2013 - Elsevier
Chronic myeloid leukaemia (CML) is characterized by the Philadelphia chromosome
resulting in the BCR-ABL1 gene whose mRNA transcript detection is commonly used for …
resulting in the BCR-ABL1 gene whose mRNA transcript detection is commonly used for …
Targeting the chronic myeloid leukemia stem cells: a paradigm for the curative treatment of human malignancies
A Woolfson, X Jiang - … New York: INTECH Open Access Publisher, 2011 - books.google.com
Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder of pluripotent
hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the …
hematopoietic stem/progenitor cells that has been paradigmatic to our understanding of the …
Where are we going with CML research?
D Perrotti - Leukemia supplements, 2012 - nature.com
The introduction of Abl tyrosine kinase inhibitors (TKI; that is, imatinib, dasatinib and
nilotinib) as front-line therapy completely changed the course of chronic myelogenous …
nilotinib) as front-line therapy completely changed the course of chronic myelogenous …